Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B3ZC
|
|||
| Former ID |
DIB000060
|
|||
| Drug Name |
Claudiximab
|
|||
| Synonyms |
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72; ICD-10: C16] | Phase 3 | [1] | |
| Esophageal cancer [ICD-11: 2B70; ICD-9: 150] | Phase 2 | [2] | ||
| Company |
Ganymed Pharmaceuticals AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | . | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01197885) Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.